None listed
Conditions
Interventions
15 mg/kg/d albendazole Type of group
Albendazole will be administered 15 mg / kg / d for two months.
Group name:Placebo Type of group
Albendazole will be administered 15 mg / kg / d for one month, then albendazole placebo for one month.
Sponsors
UNIVERSIDAD PERUANA CAYETANO HEREDIA,
Eligibility
Inclusion criteria
Inclusion criteria: - Male or female individuals between 18-65 year of age with a diagnosed of basal subarachnoid cysticercosis (including locations in the Sylvian fissure) by neuroimaging and confirmed by serology. - Willingness to accomplish the two weeks minimal hospitalization required.
Exclusion criteria
Exclusion criteria: - Previous therapy with albendazole or praziquantel. - Pulmonary tuberculosis. - Systemic disease other than neurocysticercosis that may affect therapy or short-term prognosis, including but not limited to chronic renal failurc, hepatic insufficiency, cardiac failure, and steroid-depcndent immune diseases. - Patients in unstable condition or with severe intracranial hypertension (ICH). - Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Peru, United States
Outcome results
None listed